Thursday, November 12, 2026

Shell Plans 2028 Waterflood at Gulf of Mexico Field as Global Oil Majors Extend Aging Assets

Shell will begin water injection at its Kaikias field in January 2028 to sustain production as reservoir pressure declines, joining a global trend where oil majors prioritize extracting more from existing fields over risky new exploration. The deepwater Gulf of Mexico project can extend production by 3-5 years and recover an additional 10-20% of reserves, mirroring secondary recovery strategies deployed by Equinor in the North Sea and Petrobras offshore Brazil.

ViaNews Editorial Team

February 21, 2026

Source Trace Score1 source document1 with a live linkVerifiability: Basic
Shell Plans 2028 Waterflood at Gulf of Mexico Field as Global Oil Majors Extend Aging Assets
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Shell will begin water injection operations at its Kaikias field in the Gulf of Mexico in January 2028, part of a global shift by oil majors toward squeezing more output from aging fields rather than pursuing frontier exploration. The secondary recovery project targets an additional 10-20% of original oil reserves and can extend plateau production by 3-5 years.

Kaikias started production in 2019 as a subsea tieback to the Ursa hub, 130 miles southeast of New Orleans in water depths exceeding 4,000 feet. The waterflood timeline follows typical deepwater economics, where operators initiate secondary recovery 5-10 years after first oil when production declines 20-40% from peak levels.

The strategy mirrors approaches by international operators managing mature basins. Equinor deploys waterflood at North Sea fields like Johan Sverdrup, while Petrobras uses the technique extensively in Brazil's pre-salt province. Capital discipline and regulatory hurdles make extending existing assets more attractive than developing new discoveries, particularly with oil prices fluctuating between $70-85 per barrel.

Waterflood operations inject water into reservoirs to maintain pressure and push remaining oil toward production wells. Shell's existing Mars Basin infrastructure—including the Olympus, Ursa, and Mars platforms—reduces capital costs compared to standalone developments. The Gulf of Mexico supplies roughly 15% of U.S. crude output, making secondary recovery critical as domestic shale growth slows.

The approach carries technical risks including water breakthrough in production wells, accelerated corrosion, and uncertain reservoir response. Operators must calibrate injection rates to optimize recovery without damaging well integrity or increasing water production that dilutes oil output. Shell's investment reflects industry-wide prioritization of production reliability over growth, with secondary recovery now standard practice across global offshore basins from West Africa to Southeast Asia.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· December 16, 2025
    Shell invests in Kaikias waterflood to unlock production in Gulf of America

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com